Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals Incorporated discovers, develops and markets small molecule drugs that address major unmet medical needs. The Company has eight product candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary approach, information-driven drug design, that integrates multiple technologies in biology, chemistry, and biophysics to increase the speed and success rate of drug discovery. Vertex's first approved product is Agenerase, an HIV protease inhibitor that Vertex co-promotes with Glaxo Wellcome. Vertex's goal is to develop and commercialize a range of products in the coming years. Vertex has five product candidates in Phase II clinical testing, including drugs aimed at the treatment of HIV, hepatitis C, rheumatoid arthritis, a variety of solid tumor cancers, and diabetic neuropathy.

Activity:

- Research & Development

Product / Technology type(s) covered:

- Bio
- Pharmaceuticals / Therapeutics

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active: North America , Europe

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: